Sax Wealth Advisors LLC Invests $561,000 in Illumina, Inc. (NASDAQ:ILMN)

Sax Wealth Advisors LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 4,198 shares of the life sciences company’s stock, valued at approximately $561,000.

Several other large investors have also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc increased its stake in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Private Trust Co. NA lifted its holdings in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new position in Illumina in the third quarter valued at approximately $63,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Barclays increased their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Stephens boosted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, UBS Group lifted their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Stock Down 0.5 %

ILMN opened at $136.67 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market capitalization of $21.68 billion, a PE ratio of -13.72 and a beta of 1.11. The stock’s fifty day moving average is $139.60 and its 200-day moving average is $133.37. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the business earned $0.33 earnings per share. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.